Cell-free protein expression is a new trend in biotechnology. This process involves the use of antibodies to drive viral or bacterial infections out of cells and into the bloodstream. This results in fewer toxins entering the system and fewer side effects upon exposure to microorganisms. The benefits of this practice are being determined, however, and researchers have been testing various applications of cell-free protein expression for years.
One of the benefits of cell-free protein expression is that it allows researchers to develop vaccines, medicines, and therapies that require live virus components. Without this protein, it would be impossible to manufacture these medicines and drugs. Furthermore, since these proteins have to be kept living in order for them to work, there are strict guidelines to follow to ensure that the proteins remain stable and do not harm living cells. For instance, live viruses must be kept in cell culture before they can be injected into the body. Cell-free protein expression allows researchers to use healthy cells for experimental treatments. Since the protein may be mixed with other proteins, the body can still build new cells even when it is undergoing disease. This allows scientists to study any disease more aggressively.
Since the treatment will use the patient's own cells, there is no rejection of the cells that are part of the study. Plus, these treatments have been shown to improve the immune system's ability to fight off disease. Scientists are still looking at cell-free protein expression as a way to treat certain chronic diseases. They are also researching methods for introducing the protein into the body in small amounts so that the immune system can better respond to health problems. Recently, in April 2020, SwiftScale Biologics, a biomanufacturing company, announced that is focusing on a cell-free protein expression approach in the development of COVID-19 therapeutics by using glycoengineered bacteria.
No comments:
Post a Comment